J&J | JNJ - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 688M 58M 2026-09
Abbott USD 297M 2M 2026-09
Amgen USD 653M 94.99B 2026-09
AstraZeneca USD 371M 31M 2026-09
Baxter International USD 64M 14M 2026-06
Bayer EUR 675M 87M 2025-12
Becton, Dickinson and Co. USD 130M 2M 2026-09
Biogen USD 72.6M 12.6M 2025-06
Boston Scientific USD 100M 4M 2026-09
Bristol-Myers Squibb USD 403M 4M 2026-09
CONMED USD 11.14M 3.25M 2026-09
Cooper Companies USD 21.5M 600K 2026-06
Dexcom USD 3.1M 100K 2026-09
Edwards Lifesciences USD 30M 5.9M 2026-06
Eli Lilly USD 316M 201.3M 2026-09
Gilead Sciences USD 269M 22M 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
Globus Medical USD 5.53B 39.93M 2026-09
Insulet USD 12.3M 1.3M 2026-09
Integra LifeSciences USD 22.96M 33K 2026-09
Intuitive Surgical USD 19.35B 1.53B 2026-09
J&J USD 43M 25M 2026-03
Medtronic USD 186M 10M 2026-06
Merck USD 525M 46M 2026-06
Merit Medical Systems USD 7.33M 4.78M 2026-09
Novartis USD 468M 6M 2026-09
Pfizer USD 662M 5M 2026-09
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 222M 65M 2026-09
Stryker USD 47.25B 683M 2026-09
Tandem Diabetes Care USD 1.16B 5.29M 2026-09
Teva Pharmaceutical Industries USD 414M 219M 2026-09
Vertex Pharmaceuticals USD 36M 32.7M 2026-09
Zimmer Biomet Holdings USD 23.54B 740.8M 2026-09
Zoetis USD 62M 1000K 2026-09